Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Ticagrelor Formulations in Healthy Adults
NCT03126695Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- May 2017
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ticagrelor in sickle cell disease (SCD) (4 arms), sponsored by AstraZeneca. Primary endpoints: Maximum observed plasma concentration at 48 hours and Area under plasma concentration-time curve from zero to infinity at 48 hours. Started May 2017; status: completed.
02
Drugs
ticagrelor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03126695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03126695.